Surface-Expressed Enolase Contributes to the Pathogenesis of Clinical Isolate SSU of *Aeromonas hydrophila*™

Jian Sha,1,3 Tatiana E. Erova,1,3 Rebecca A. Alyea,1,3 Shaofei Wang,1,3 Juan P. Olano,2,3 Vijay Pancholi,4 and Ashok K. Chopra1,3*  

Departments of Microbiology and Immunology1 and Pathology,2 Institute of Human Infections and Immunity, and Sealy Center for Vaccine Development,3 University of Texas Medical Branch, Galveston, Texas 77555, and Ohio State University College, Columbus, Ohio 432104  

Received 2 January 2009/Accepted 17 February 2009

In this study, we demonstrated that the surface-expressed enolase from diarrheal isolate SSU of *Aeromonas hydrophila* bound to human plasminogen and facilitated the latter's tissue-type plasminogen activator-mediated activation to plasmin. The bacterial surface-bound plasmin was more resistant to the action of its specific physiological inhibitor, the antiprotease α1-antiplasmin. We found that immunization of mice with purified recombinant enolase significantly protected the animals against a lethal challenge dose of wild-type (WT) *A. hydrophila*. Minimal histological changes were noted in organs from mice immunized with enolase and then challenged with WT bacteria compared to severe pathological changes found in the infected and nonimmunized group of animals. This correlated with the smaller bacterial load of WT bacteria in the livers and spleens of enolase-immunized mice than that found in the nonimmunized controls. We also showed that the enolase gene could potentially be important for the viability of *A. hydrophila* SSU as we could delete the chromosomal copy of the enolase gene only when another copy of the targeted gene was supplied in trans. By site-directed mutagenesis, we altered five lysine residues located at positions 343, 394, 420, 427, and 430 of enolase in *A. hydrophila* SSU; the mutated forms of enolase were hyperegulated in *Escherichia coli*, and the proteins were purified. Our results indicated that lysine residues at positions 420 and 427 of enolase were crucial in plasminogen-binding activity. We also identified a stretch of amino acid residues (252FYDAEKKEY260) in the *A. hydrophila* SSU enolase involved in plasminogen binding. To our knowledge, this is the first report of the direct involvement of surface-expressed enolase in the pathogenesis of *A. hydrophila* SSU infections and of any gram-negative bacteria in general.

*Aeromonas hydrophila* is an emerging human pathogen that causes gastroenteritis and other extraintestinal infections, such as septicemia, meningitis, pneumonia, cellulitis, bullous lesions, and ecthyma gangrenosum (8, 43). The increasing isolation of this organism from water and food, as well as its resistance to water chlorination specifically in biofilms and to various antibiotics, could be a public health threat (16, 43). In this study, we demonstrated that the surface-expressed enolase from diarrheal isolate SSU of *Aeromonas hydrophila* bound to human plasminogen and facilitated the latter's tissue-type plasminogen activator-mediated activation to plasmin. The bacterial surface-bound plasmin was more resistant to the action of its specific physiological inhibitor, the antiprotease α1-antiplasmin. We found that immunization of mice with purified recombinant enolase significantly protected the animals against a lethal challenge dose of wild-type (WT) *A. hydrophila*. Minimal histological changes were noted in organs from mice immunized with enolase and then challenged with WT bacteria compared to severe pathological changes found in the infected and nonimmunized group of animals. This correlated with the smaller bacterial load of WT bacteria in the livers and spleens of enolase-immunized mice than that found in the nonimmunized controls. We also showed that the enolase gene could potentially be important for the viability of *A. hydrophila* SSU as we could delete the chromosomal copy of the enolase gene only when another copy of the targeted gene was supplied in trans. By site-directed mutagenesis, we altered five lysine residues located at positions 343, 394, 420, 427, and 430 of enolase in *A. hydrophila* SSU; the mutated forms of enolase were hyperegulated in *Escherichia coli*, and the proteins were purified. Our results indicated that lysine residues at positions 420 and 427 of enolase were crucial in plasminogen-binding activity. We also identified a stretch of amino acid residues (252FYDAEKKEY260) in the *A. hydrophila* SSU enolase involved in plasminogen binding. To our knowledge, this is the first report of the direct involvement of surface-expressed enolase in the pathogenesis of *A. hydrophila* SSU infections and of any gram-negative bacteria in general.

1Corresponding author. Mailing address: Department of Microbiology and Immunology, 301 University Blvd., Medical Research Building, UTMB, Galveston, TX 77555-1070. Phone: (409) 747-0578. Fax: (409) 747-6869. E-mail: achopra@utmb.edu.

2Published ahead of print on 6 March 2009.
specific physiological inhibitors (e.g., the antiprotease α1-antiplasmin [α1-AP]) (17, 20). Plasmin is a trypsin-like serine protease with broad substrate specificity; it is physiologically involved in fibrinolysis by degradation of fibrin and also degrades noncollagenous glycoproteins of mammalian extracellular matrices and basement membranes. Thus, surface-expressed plasminogen receptors (e.g., enolase) provide a niche for host cells or bacteria to interact with the mammalian proteolytic plasminogen-plasmin system, which presumably facilitates the metastasis process or promotes microbial pathogens to migrate within the host to fulfill their nutritional demands (18, 19, 21, 22, 23, 25). Indeed, several recent studies demonstrated that enolase in certain pathogenic bacteria (e.g., Streptococci and Pseudomonocci) and microbiota (e.g., Lactobacilli and Bifidobacteria) not only is essential for bacterial viability because of its enzymatic activity but also promotes pathogen-host interactions and contributes to bacterial colonization and pathogenesis by means of its surface or extracellular location (1, 4, 6, 17, 19, 20, 22, 26, 27). In our previous study, we reported the presence of surface-expressed enolase in the gram-negative bacterium A. hydrophila SSU (32) and demonstrated that crude, whole-bacterial-cell lysates of A. hydrophila could bind human plasminogen (32). However, the direct role of enolase in Aeromonas infections has not yet been established.

In our present study, we provided direct evidence that the washed whole bacterial cells of A. hydrophila SSU bound human plasminogen/plasmin and facilitated tPA-mediated activation of plasminogen. We also found that this plasminogen/plasmin-bacterial cell interaction was, in part, mediated by enolase. We immunized mice with purified recombinant enolase and showed that such immunized animals were protected against mortality from a lethal challenge dose of wild-type (WT) A. hydrophila. However, we were unable to develop an enolase-negative mutant of A. hydrophila SSU, which suggests that this enzyme might be essential for the viability of this organism. Further, we studied enolase’s plasminogen-binding activity in A. hydrophila SSU and identified lysine residues at positions 420 and 427 that contributed to this activity. We also identified an internal stretch of amino acid residues \( \text{F} \text{E} \text{K} \text{E} \text{Y} \text{S} \text{S} \text{G} \) in the enolase (which has 434 amino acid residues) of A. hydrophila SSU that was responsible for this plasminogen-binding activity. This is the first detailed study illustrating the role of enolase in the pathogenesis of A. hydrophila SSU infections.

**Materials and Methods**

**Bacterial strains, plasmids, media, and DNA techniques.** The bacterial strains and plasmids (10, 24, 33) used in this study are listed in Table 1. A. hydrophila SSU, a diarreal isolate, was obtained from the Centers for Disease Control and Prevention, Atlanta, GA. SSU-R is a spontaneous rifampin-resistant (Rif') strain of SSU that was prepared previously in our laboratory (35). Lucia Bertani (LB) broth (Difco Laboratories, Detroit, MI) was used to grow A. hydrophila and Escherichia coli cultures at 37°C with aerobation (180 rpm). The antibiotics ampicillin (Ap), tetracycline (Tc), kanamycin (Km), streptomycin (Sp), spectinomycin (Sm), and Rif were obtained from Sigma (St. Louis, MO) and were used at concentrations of 100, 15, 50, 25, and 40 μg/ml, respectively. Restriction endonucleases were purchased from Promega (Madison, WI). All of the basic molecular biology techniques used in this study were described previously (12).

**Plasminogen binding to A. hydrophila SSU cells and activation of plasminogen.** The tPA-mediated activation of plasminogen in the presence of bacteria was measured as described by Lahteenmäki et al. (20). Briefly, 4 × 10^9 log-phase-grown, phosphate-buffered saline (PBS)-washed A. hydrophila SSU cells were incubated with 4 μg of human plasminogen (Sigma), 2 ng of tPA (Molecular Innovations, Inc., Novi, MI) and a 0.45 mM concentration of the chromogenic plasmin substrate S-2251 (DiaPharma Group, Inc., West Chester, OH) in a final volume of 200 μl in PBST buffer (PBS containing 0.02% Tween 80). In some reaction mixture groups, 2 mM ε-aminocaproic acid (EACA; Sigma) or purified immunoglobulin G (IgG) at concentrations of 0.125 mg/ml and 0.025 mg/ml from enolase-immunized and preimmune mouse serum (as stated in the animal experiment section below) was added. The reaction mixture groups that did not contain both the bacterial cells or the tPA served as negative controls. The reaction mixtures were incubated at 37°C with slow rotation, and the increased plasmin activity was assessed at a 30-min interval for a total of 3 h by measuring absorbance at 405 nm with a VERSAmax tunable microplate reader (Molecular Devices Corporation, Sunnyvale, CA).

For the binding assay, 8 × 10^7 A. hydrophila SSU cells treated similarly as above were incubated with either 4 μg of human plasminogen plus 2 ng of tPA or 4 μg of human plasminogen only (Sigma) in a final volume of 200 μl in PBST buffer. The reaction mixtures were incubated at 37°C with slow rotation for 3 h. In some reaction mixture groups, 2 mM EACA or purified IgG (0.125 mg/ml and 0.025 mg/ml) from enolase-immunized and preimmune mouse serum was added into the reaction mixture. The reaction mixture groups that contained only bacterial cells without the addition of plasminogen and plasmin served as negative controls. After incubation, the bacterial cells were collected and washed twice with PBST buffer and were finally resuspended in 300 μl of PBST buffer containing 0.45 mM S-2251. We incubated the reaction mixtures at 37°C for 2 h and measured plasmin activity at 405 nm. The plasmin activity levels in the negative control reaction mixture groups were used as blanks in the measurement.

For analyzing the protection of plasmin from α1-AP in the presence of bacterial cells, plasmin (0.25 μg or 2.5 μg) was incubated with or without 4 × 10^9 phase-grown, PBS-washed A. hydrophila SSU cells for 30 to 60 min at room temperature prior to the addition of 0.45 mM S-2251 and α1-AP in increasing concentrations (1, 8, and 16 μg). Plasmin activity was measured after 1 h of incubation at 37°C. The reaction mixture groups that were omitted from either the α1-AP or both bacterial cells and α1-AP cultures were used as controls. The viability of bacterial cells was monitored by serial dilution and plating at the end of each of the above experiments.

**Generation and characterization of enolase gene mutant of A. hydrophila SSU.** Two pairs of primers, enoAPsenou3 and enoASendsn3 (Table 2), were synthesized and used to amplify the upstream (796 bp) and downstream (718 bp) flanking DNA sequences to the enolase gene of A. hydrophila. These fragments were then ligated together through the introduced common BglII site and cloned into a PET3a vector (37) at the NotI/XbaI restriction sites, resulting in the recombinant plasmid pETUD (Table 1). An Sm/Sp cassette flank by the BamHI site was removed from the plasmid pHP450 (33) and inserted at the BglII site (compatible with the BamHI site) of pETUD to generate the recombinant plasmid pETUDSm/Sp (Table 1). After digestion with NotI/XbaI restriction enzymes, the DNA fragment (3.5 kb) from the above plasmid was removed and ligated into (a) to pBudESp vector(33) at the compatible restriction enzyme sites to generate the recombinant plasmid pBUDSm/Sp (Table 1). By using KpnI/XbaI restriction enzymes, the DNA fragment (3.5 kb) was removed from the plasmid pBUDSm/Sp and ligated to the pDM197 suicide vector at the compatible restriction site, and the resulting plasmid (pDM197Sm/Sp) was transformed into E. coli SM10 (24, 33). The recombinant E. coli [pDM197Sm/Sp] was conjugated with the parental Rif A. hydrophila strain (33). The transconjugants were selected based on their resistance to appropriate antibiotics and sucrose and subjected to further analysis (33).

**Supplying an additional copy of the native enolase gene into WT A. hydrophila SSU.** Primers eno5 and eno3 (Table 2) were used to PCR amplify the coding region of the enolase gene from A. hydrophila. The amplified DNA fragment (1,313 bp) was cloned into the pBR322 vector at the Scel/PstI restriction enzyme sites, generating the recombinant plasmid pBReno (Table 1). In this plasmid, the enolase gene was under the control of an Ap resistance gene promoter of the vector, and, therefore, it was constitutively expressed. The recombinant plasmid pBReno was subsequently electroporated into WT A. hydrophila (14). The presence of recombinant plasmid pBReno in WT A. hydrophila was verified by plasmid isolation and digestion with Scel and PstI restriction enzymes.

**Generation of various mutated forms of the enolase gene by site-directed mutagenesis.** An Altered Sites in vitro Mutagenesis System (Promega) was used for site-directed mutagenesis as described previously (12). Briefly, the coding region of the native enolase gene was PCR amplified from the genomic DNA of WT A. hydrophila with the primer set enoF/enoR (Table 2) and subsequently cloned into the plasmid pALTER-1 (Tc' Ap'), generating the recombinant plasmid pALTER-1/eno (Tc' Ap') (Table 1). Subsequently, E. coli JM109 cells
from these bacterial strains was then transformed into E. coli generated a specific mutated enolase gene in plasmid pALTER-1 and was transformed with the plasmid pBreno; SmSp Rif Te.

L420, eno

tions with the individual mutagenic primers described by the manufacturer. This single-stranded DNA was used as a template for the mutagenesis reaction.

L420, eno

The chromosomal enolase gene was deleted from WT A. hydrophila SSU-R that was transformed with the plasmid pBreno; SmSp Rif Te.

E. coli

SM10

Km' apr

cDNA was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'.

pET30aeno

The native enolase gene of A. hydrophila was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'.

pET30aeno343K/Q

The mutated enolase gene of A. hydrophila eno(K343Q) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'.

pET30aeno343K/M

The mutated enolase gene of A. hydrophila eno(K343M) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'.

pET30aeno420K/L

The mutated enolase gene of A. hydrophila eno(K420L) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'.

pET30aeno427K/N

The mutated enolase gene of A. hydrophila eno(K427N) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'.

pET30aeno430K/R

The mutated enolase gene of A. hydrophila eno(K430R) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'.

<table>
<thead>
<tr>
<th>Strain or plasmid</th>
<th>Relevant characteristic(s) and/or construction</th>
<th>Source or reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. hydrophila SSU</td>
<td>Rif' strain of A. hydrophila SSU</td>
<td>CDC, Atlanta, GA</td>
</tr>
<tr>
<td>WT/pBreno</td>
<td>WT A. hydrophila SSU-R transformed with pBreno plasmid; Rif' Te'</td>
<td>Laboratory stock</td>
</tr>
<tr>
<td>Enolase mutant</td>
<td>The chromosomal enolase gene was deleted from WT A. hydrophila SSU-R that was transformed with the plasmid pBreno; SmSp Rif' Te'</td>
<td>This study</td>
</tr>
<tr>
<td>E. coli</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SM10</td>
<td>Km' apr</td>
<td></td>
</tr>
<tr>
<td>JM109</td>
<td>endA1 recA1 gyrA96 thi-1 hsdR17(k' mK') relA1 supE44 Δ lac-proAB [ F' traD36 proAB lacPZΔM15 ]</td>
<td>Promega</td>
</tr>
<tr>
<td>ES1301 mutS</td>
<td>lacZ53 mutS205::Tn5 thyA36 rha-5 metB1 deoC</td>
<td>Promega</td>
</tr>
<tr>
<td>HMS174 (DE3)</td>
<td>RecA-mutated K-12 background E. coli strain that carries a chromosomal copy of the T7 RNA polymerase gene under the control of the lacUV5 promoter; used as the host strain for the pET expression system</td>
<td>Novagen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strains</th>
<th>Relevant characteristic(s) and/or construction</th>
<th>Source or reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. hydrophila SSU</td>
<td>Rif' strain of A. hydrophila SSU</td>
<td>CDC, Atlanta, GA</td>
</tr>
<tr>
<td>WT/pBreno</td>
<td>WT A. hydrophila SSU-R transformed with pBreno plasmid; Rif' Te'</td>
<td>Laboratory stock</td>
</tr>
<tr>
<td>Enolase mutant</td>
<td>The chromosomal enolase gene was deleted from WT A. hydrophila SSU-R that was transformed with the plasmid pBreno; SmSp Rif' Te'</td>
<td>This study</td>
</tr>
<tr>
<td>E. coli</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SM10</td>
<td>Km' apr</td>
<td></td>
</tr>
<tr>
<td>JM109</td>
<td>endA1 recA1 gyrA96 thi-1 hsdR17(k' mK') relA1 supE44 Δ lac-proAB [ F' traD36 proAB lacPZΔM15 ]</td>
<td>Promega</td>
</tr>
<tr>
<td>ES1301 mutS</td>
<td>lacZ53 mutS205::Tn5 thyA36 rha-5 metB1 deoC</td>
<td>Promega</td>
</tr>
<tr>
<td>HMS174 (DE3)</td>
<td>RecA-mutated K-12 background E. coli strain that carries a chromosomal copy of the T7 RNA polymerase gene under the control of the lacUV5 promoter; used as the host strain for the pET expression system</td>
<td>Novagen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 1. Strains and plasmids used in this study</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Strain or plasmid</td>
<td>Relevant characteristic(s) and/or construction</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>pHP145</td>
<td>Contains a 2.0-kb SmSp' gene cassette</td>
</tr>
<tr>
<td>pET30a</td>
<td>pBR322-derived expression vector with T7 lac promoter and up- and down-stream His tags; Km'</td>
</tr>
<tr>
<td>pDMS197</td>
<td>A suicide vector; RsK ori sacB Te' Ap'</td>
</tr>
<tr>
<td>pALTER-1</td>
<td>Vector for the site mutagenesis; Te' Ap'</td>
</tr>
<tr>
<td>pBreno</td>
<td>The coding region of A. hydrophila enolase gene was cloned in pBR322 at the Scal/PstI sites and under the control of the Ap promoter of the vector; Te'</td>
</tr>
<tr>
<td>pETUD</td>
<td>pET30a vector containing up- and downstream DNA flanking sequences to the enolase gene; Km'</td>
</tr>
<tr>
<td>pETUDSm/Sp</td>
<td>The SmSp cassette was ligated with the up- and downstream DNA flanking sequences to the enolase gene in pET30a vector; SmSp' Km'</td>
</tr>
<tr>
<td>pBUDSm/Sp</td>
<td>The SmSp cassette was ligated with the up- and downstream DNA flanking sequences to the enolase gene in pBluescript vector; SmSp' Ap'</td>
</tr>
<tr>
<td>pDMSUDSm/Sp</td>
<td>Suicide vector pDMS197 containing the SmSp cassette ligated with up- and downstream DNA flanking sequences to the enolase gene; used to generate the enolase gene deletion mutant of A. hydrophila; Km' Te'</td>
</tr>
<tr>
<td>pALTER-1/eno</td>
<td>The native enolase gene of A. hydrophila was cloned into pALTER-1 vector at the BamHI/HindIII sites for the site mutagenesis; Te' Ap'</td>
</tr>
<tr>
<td>pALTER/eno343K/Q</td>
<td>pALTER-1 vector containing the mutated A. hydrophila enolase gene eno(K343Q); Te' Ap'</td>
</tr>
<tr>
<td>pALTER/eno343K/M</td>
<td>pALTER-1 vector containing the mutated A. hydrophila enolase gene eno(K343M); Te' Ap'</td>
</tr>
<tr>
<td>pALTER/eno420K/L</td>
<td>pALTER-1 vector containing the mutated A. hydrophila enolase gene eno(K420L); Te' Ap'</td>
</tr>
<tr>
<td>pALTER/eno427K/N</td>
<td>pALTER-1 vector containing the mutated A. hydrophila enolase gene eno(K427N); Te' Ap'</td>
</tr>
<tr>
<td>pET30aeno</td>
<td>pALTER-1 vector containing the mutated A. hydrophila enolase gene eno(K430R); Te' Ap'</td>
</tr>
<tr>
<td>pET30aeno343K/Q</td>
<td>The mutated enolase gene of A. hydrophila eno(K343Q) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'</td>
</tr>
<tr>
<td>pET30aeno343K/M</td>
<td>The mutated enolase gene of A. hydrophila eno(K343M) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'</td>
</tr>
<tr>
<td>pET30aeno420K/L</td>
<td>The mutated enolase gene of A. hydrophila eno(K420L) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'</td>
</tr>
<tr>
<td>pET30aeno427K/N</td>
<td>The mutated enolase gene of A. hydrophila eno(K427N) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'</td>
</tr>
<tr>
<td>pET30aeno430K/R</td>
<td>The mutated enolase gene of A. hydrophila eno(K430R) was cloned in pET30a and fused with the downstream His tags of the vector for hyperexpression; Km'</td>
</tr>
</tbody>
</table>
The IPTG-induced bacterial cells were harvested, and the cell lysates from these enolase-expressing strains were first passed through a ProBond nickel chelating column (Invitrogen, Carlsbad, CA) and loaded onto an ion exchange Resource Q column (6 ml; 100/100). The proteins were eluted from the column by using a salt gradient (20 mM Tris, 1 M NaCl, 5 mM MgSO4, and 1 mM DTT, pH 6.5) and loaded onto a m-pore-size syringe filter (Corning/H9262). The dialyzed fractions were filtered through a 22-kDa molecular-mass-cutoff tubing) for 12 h at 4°C in a buffer containing 20 mM Tris, 0.25% gelatin) (40). An aliquot (2 g per well of purified and different forms of recombinant enolase was coated with 2 g of human plasminogen. The overnight coated plates were washed and then blocked overnight at 4°C. For the positive control, the plate wells were coated with 2 µg of human plasminogen (Sigma) while wells coated with PBS only were used as negative controls. Eight wells were used for each tested recombinant enolase and control. The overnight coated plates were washed and then blocked overnight again at 4°C with buffer A (PBS containing 0.05% Tween 20, 1 mM EDTA, and 0.25% gelatin) (40). An aliquot (2 µg of plasminogen in 50 µl of PBS was added to the coated wells and incubated for 2 h at room temperature. In some experiments, EACA or peptides (see below) were mixed with 2 µg of human plasminogen before being added to the microtiter plate wells to allow us to study their abilities to block enolase binding to the plasminogen. We used EACA at concentrations of 2, 4, 6, and 8 mM and the three peptides Snn (FYDERKVR), Aeno (FYDAKGEK), and AenoM (FYDAKGEK), representing regions within the Streptococcus pneumoniae and A. hydrophila SSU enolases, at concentrations of 100 to 200 µg/well. The AenoM peptide had two amino acid substitutions (underlined) compared to the peptide Aeno.

Peptide Snn represented an internal plasminogen-binding motif (amino acid residues 248 to 256) identified in the enolase of S. pneumoniae (3, 11), while peptide Aeno (amino acid residues 252 to 260) represented a corresponding stretch of Snn in the enolase of A. hydrophila SSU (11). Peptide AenoM was the mutated form of Aeno, and the substituted amino acid residues were indicated by underlining in the sequence shown above. These peptides were synthesized by the BioMatic Corporation (Toronto, Ontario, Canada) and reconstituted in water at a concentration of 5 mg/ml. After a 2-h incubation, the plates were washed three times with buffer A and incubated for 1 h with goat antiplasminogen antibodies (primary antibody; 1:1,500 dilution) followed by horseradish peroxidase-labeled mouse, anti-goat IgG (secondary antibody; 1:2,000 dilution) (Santa Cruz Biotechnology, Inc.) (32). TMB (3,3,5,5-tetramethyl benzidine) substrate) was used for color development, and the optical density (sub-
tracted from the blanks, i.e., the wells coated with PBS and used as the negative control) was read at 370 nm by using a VERSAmax tunable microplate reader.

**Animal experiments.** Groups of 15 Swiss Webster mice (Taconic Farms, Germantown, NY) were first immunized with purified native (unmutated) recombinant enolase produced from *E. coli*. Briefly, animals were injected intraperitoneally (i.p.) with 10 μg of purified enolase mixed with monophosphoryl lipid A-trehalose dicorynomycolate-cell wall skeleton adjuvant (Sigma). The animals were bled before immunization, boosted twice with the antigen (10 μg) at 15-day intervals, and finally bled after 1 month. The antibody titers in the pooled sera were determined by using an ELISA having recombinant enolase as the antigen source (33). The immunized and nonimmunized mice (given the guadient alone without the antigen) were challenged i.p. with the WT *A. hydrophila* SSU at two to three times the 50% lethal dose ([LD$_{50}$] 5 × 10$^8$ to 1 × 10$^9$ CFU) after 1 month of immunization. Organs (lungs, spleen, and liver) from five mice in each group were removed at day 3 of the challenge and subjected to analyses for histopathology and bacterial load (liver and spleen), as we recently described (31). Five noninfected mice were used as controls for the histopathological study. The deaths of mice were recorded, and the animals were monitored for 3 weeks postinfection.

The IgGs from the enolase-immunized and preimmune mouse sera collected from the above animal experiment were purified by using Nab Spin Kits (Thermo Fisher Scientific Inc., Rockford, IL) and further desalted with a Zeba Desalt Spin column (Thermo). The enolase antibody titers in the purified IgGs were further evaluated by ELISA using purified native recombinant enolase as the antigen source. The amount of purified IgG in both preimmune and immune sera was determined by using a Bradford dye protein assay (5). The purified IgGs were stored at 4°C and employed in the phagocytosis assay and plasminogen-binding and activation assays as described above.

**Phagocytosis assay.** An aliquot (1 × 10$^9$) of log-phase-grown, PBS-washed *A. hydrophila* SSU cells was incubated with purified IgGs from either enolase-immunized or preimmune mouse sera at concentrations of 0.125 mg/ml and 0.025 mg/ml in a final volume of 300 μl in PBS. The bacterial cells incubated with PBS served only as negative controls. After a 1-h incubation at 37°C, the bacterial cells were washed three times with PBST buffer, and a portion of the bacterial cells was serially diluted and plated to examine viability of the bacterial cells after they were coated with the antibodies. The rest of the bacterial cells were used to infect RAW 264.7 murine macrophages (in six-well tissue culture plates) at a multiplicity of infection of 1 (37). The wells were done in triplicate for each infection group. After 3 h of incubation at 37°C with 5% CO$_2$, the infected macrophages were washed twice with PBS and then incubated an additional hour in fresh Dulbecco’s modified essential medium containing 200 μg/ml gentamicin.

The gentamicin treatment killed extracellular bacteria but did not affect the viability of intracellular organisms. The macrophages were then washed three times with PBS to remove gentamicin and lysed with 200 μl of 1% (vol/vol) Triton X-100 to release intracellular bacteria. A 10-fold serial dilution was made, and bacteria were enumerated on LB agar plates in duplicate.

**Statistical analysis of the data.** Where applicable, a minimum of three independent experiments were performed, and the data were analyzed using either a Student’s t test or Fisher’s exact test.

## RESULTS

**Immobilization and conversion of plasminogen to plasmin on the cell surface of *A. hydrophila* SSU cells.** In our previous study, we detected strong enolase activity associated with the intact *A. hydrophila* cells and demonstrated that crude, whole-bacterial-cell lysates of *A. hydrophila* could bind human plasminogen (32). To further investigate whether plasminogen indeed binds to the bacterial surface, the log phase and PBS-washed *A. hydrophila* SSU cells were first incubated with human plasminogen. After the unbound plasminogen was washed away, the surface-bound plasminogen was further converted to the active form of plasmin by iPA, and the plasmin activity was measured by adding the plasmin-specific chromogenic substrate S-2251.

As shown in Fig. 1A, plasmin activity was detected on the cell surface of *A. hydrophila* SSU cells (column a), and addition of the lysine analog EACA decreased bacterial surface-associated plasmin activity by 56% (column b). These data indicated that plasminogen binding to the bacterial surface was specific and that lysine residues were involved. Importantly, we observed a dose-dependent decrease in plasmin activity (29 to 46%) in the reaction mixture groups in which purified enolase-specific antibodies were added (columns c and d). As expected, there was no decrease in plasmin activity compared to that of the control (column a) when purified IgGs from preimmune sera were added to the reaction mixtures (columns e and f).

Overall, these data indicated to us that the bacterial surface-plasminogen interaction was mediated in part by enolase. A similar pattern was noticed when human plasmin was directly incubated with *A. hydrophila* SSU cells (Fig. 1B). No significant changes in the number of bacterial cells were observed before or after the experiment in each group and among the groups, which suggested to us that the viability of *A. hydrophila* SSU was not affected during the experiment.

**Plasminogen binding on the surface of *A. hydrophila* SSU cells promoted its iPA-mediated activation and protected plasmin from its physiological inhibitor e$_4$AP.** As shown in Fig. 2, there was a significant, time-dependent (30 to 180 min) formation of plasmin from plasminogen mediated by iPA (group A) in the presence of *A. hydrophila* SSU cells. In contrast, only...
marginal plasmin activity was observed in the group in which no bacterial cells were added (group E). Plasmin formation was greatly inhibited (32 to 61%) over a period of 3 h of incubation in the presence of EACA (group B) compared to that in the control group A, a finding that further emphasized lysine residue involvement and the importance of plasminogen’s binding to the bacterial surface prior to its activation.

Compared to the groups of reaction mixtures with the addition of purified IgGs from preimmune sera (group D), the presence of enolase-specific antibodies in the reaction mixtures significantly and dose-dependently decreased (12 to 43%) tPA-mediated plasmin formation (group C), with a maximum decrease (43%) occurring at the 60-min time point. In Fig. 2, data represent only experiments with high (0.125 mg/ml) enolase antibody concentrations. When a lower concentration of enolase antibodies (0.025 mg/ml) was used in the reaction mixtures, the decrease in plasmin activity was in the range of 8 to 31% over a period of 3 h, with statistical differences compared to the preimmune sera only at 30- and 60-min time points (data not shown). These data further confirmed that enolase was involved in plasminogen binding and its activation.

Minimal plasmin formation was noticed in the reaction mixture in which no tPA was added (group F), suggesting to us that there was no apparent plasminogen activator secreted by A. hydrophila SSU.

To test if the converted plasmin on the surface of A. hydrophila SSU cells was protected from the action of its specific inhibitor, bacterial cells were incubated with 0.25 μg of plasmin for 30 to 60 min before different amounts of the plasmin inhibitor α2AP were added. As shown in Fig. 3, compared to the control groups in which α2AP (control A) or both the bacterial cells and α2AP (control B) were omitted, groups receiving α2AP at various concentrations showed a statistically significant 46 to 54% decrease in plasmin activity, even in the presence of A. hydrophila cells. However, in the groups of reaction mixtures in which no bacterial cells were added, α2AP abrogated plasmin activity (above 90% inhibition), which indicated that A. hydrophila SSU cells provided partial protection to plasmin from the action of its physiological inhibitor α2AP. A similar pattern was observed when a larger amount of plasmin (2.5 μg) was used in this protection assay (data not shown).

Role of lysine residues in the enzymatic and plasminogen-binding activities of A. hydrophila enolase. To further study the plasminogen-binding activity of enolase, we used purified recombinant A. hydrophila SSU enolase from E. coli. As shown in Fig. 4, the recombinant enolase-bound plasminogen was detected by the antiplasminogen antibody in ELISA. Importantly, this plasminogen-binding activity could also be blocked by adding EACA (lysine analog) in a dose-dependent manner. These data with the purified enolase corroborate the results shown in the plasminogen-binding and activation experiments (Fig. 1 to 3) with whole bacterial cells and confirmed the role of lysine residues of enolase in plasminogen binding.

To confirm this finding, we mutated lysine residues of the A. hydrophila SSU enolase at positions 343, 394, 420, 427, and 430 by site-directed mutagenesis and generated five mutated forms of enolase, designated Eno(K343Q), Eno(K394M), Eno(K420L), Eno(K427N), and Eno(K430R), respectively. These lysine residues were chosen either because their positions were toward the carboxyl terminus of A. hydrophila SSU enolase, which has 434 amino acid residues (e.g., lysine residues 420, 427, and 430), or because their corresponding lysine residues (e.g., lysine residues 343 and 394) were important to the enolase activity of Strepto-
coccus pyogenes (26). As with the native form of recombinant enolase, the mutated enolase genes were hyperexpressed, and the resulting recombinant proteins were purified. The integrity and purity of the recombinant enolase were examined by SDS–12% PAGE and Coomassie blue staining (Fig. 5A, inset). As shown in Fig. 5A, compared to the native recombinant enolase, the plasminogen-binding activities of Eno(K420L) and Eno(K427N) were decreased by 49 to 60%, respectively, while the binding activity remained similar to that of the native recombinant enolase in Eno(K343Q), Eno(K394M), and Eno(K430R). Interestingly, the enzymatic activity in all of the mutated forms of enolase was severely affected, with minimal activities (21%, 10%, and 35% of the native recombinant enolase activity, respectively) detected in Eno(K343Q), Eno(K427N), and Eno(K430R) (Fig. 5B). Importantly, Eno(K394M) and Eno(K420L) exhibited no detectable enolase activity. These findings were interesting as Eno(K394M) affected enolase activity but not the plasminogen-binding activity of enolase, while Eno(K420L) affected both of these activities.

**Plasminogen-binding motif of enolase in A. hydrophila SSU.**

It has been recently reported that a 9-amino-acid stretch of enolase ([256]FYDKERKVY268) in *S. pneumoniae* is also responsible for plasminogen-binding activity (3). By sequence comparison, a corresponding stretch (FYDAEKKKEY) was identified at amino acid residues 252 to 260 in the enolase of *A. hydrophila* SSU (11). The latter shared a 60% identity with similar stretches identified in *S. pneumoniae* and *Leishmania mexicana* enolase (Fig. 6A) (11, 40). To delineate the role of this stretch in the binding of enolase to plasminogen, peptides corresponding to these stretches (for both *S. pneumoniae* and *A. hydrophila*) were synthesized. These peptides were Seno (FYDKERKYY), Aeno (FYDAEKKKEY), and AenoM (FYDAGKLEY). Peptide AenoM is a mutated form of Aeno, and in the forging sequence, the two amino acid substitutions are underlined.

As shown in Fig. 6B, when wells were coated with the native recombinant *A. hydrophila* SSU enolase, the addition of peptides Seno and Aeno to the reaction mixtures led to a 40 to 54% reduction in the enolase-plasminogen-binding activities compared to the reaction mixtures without the addition of peptides. These data indicated that the peptides Seno and Aeno competed with the coated enolase, thus inhibiting enolase-plasminogen-binding activity. However, when the mutated

---

**References:**
peptide (AenoM) was used, no such blocking effects were noticed, thus showing that the blocking effects of peptides Seno and Aeno were specific and that the corresponding amino acid stretch (positions 252 to 260) in the enolase of *A. hydrophila* SSU had a function similar to that of the plasminogen-binding motif identified in the enolase of *S. pneumoniae* (3, 11).

Interestingly, when peptide Aeno was added to the wells coated with the mutated forms of enolase [i.e., Eno(K420L) and Eno(K427N)], we noted a further 57 to 60% reduction in plasminogen binding to mutated enolase in comparison to the wells receiving the mutated peptide AenoM or no peptides (Fig. 6B). These data indicated that the lysine residue at position 420 or 427, along with the amino acid stretch FYDAEKKEY of *A. hydrophila* SSU enolase, had an additive effect on plasminogen binding.

**Potential role of the enolase gene in the viability of *A. hydrophila***

To study the contribution of enolase in the pathogenesis of *Aeromonas* infections, we first attempted to generate an enolase-negative isogenic mutant of *A. hydrophila*. However, after several attempts, we failed to obtain the enolase knockout mutant of *A. hydrophila* SSU, thus raising the possibility that enolase might be essential for the viability of *A. hydrophila*. To test this, an additional copy of the *A. hydrophila* enolase gene was supplied via plasmid pBR322 to the WT *A. hydrophila* before conjugation (Fig. 7). Consequently, we obtained four colonies on the selected LB agar plates (containing 5% sucrose, 25 μg of Sp/Sm, and 200 μg of Rif). To confirm the deletion of the chromosomal copy of the enolase gene in these *A. hydrophila* mutant clones, two pairs of primers were synthesized. One set was Sm5/Sm3 (Table 2 and Fig. 7), which corresponded to the coding region of the Sm/Sp gene cassette, and another was ENT5/ENT3 (Table 2 and Fig. 7), representing regions of the genomic DNA just outside of the sequences to which primers enoup5 and enon3, respectively, were designed. Therefore, primers ENT5 and ENT3 were not within the flanking DNA sequences used for homologous recombination to generate the enolase mutant of *A. hydrophila*.

By using primers Sm5/Sm3, we PCR amplified a 1.0-kb segment of the Sm/Sp gene-coding region from the tested colonies, which was evidence of the integration of the Sm/Sp cassette in these clones (data not shown). The primers ENT5/Sm3 and ENT3/Sm5 were used to examine the DNA sequences adjacent to the Sm/Sp integration site after homologous recombination. As the corresponding primer binding sequences for ENT5 and ENT3 existed only on the chromosome of *A. hydrophila* (Fig. 7) and neither the plasmid pBreno nor pDMSUDSm/Sp contained the binding sequences for ENT5/ENT3, we expected specific PCR amplifications from the chromosome of the tested colonies. As shown in Fig. 7B, lanes 2 to 5, 2.3-kb and 2.1-kb DNA fragments were PCR amplified from the chromosomes of these tested clones when primer sets ENT5/Sm3 (panel I) and ENT5/Sm3 (panel II) were used. No band was amplified from WT *A. hydrophila* transformed with pBreno (Fig. 7B, lane 6), which indicated to us the correct location of the integration, which resulted in the replacement of a chromosomal copy of the enolase gene with an Sm/Sp cassette. The integrity of the native enolase gene on the plasmid pBreno in these colonies was confirmed by plasmid isolation and restriction enzyme analysis (data not shown).
Role of enolase in the pathogenesis of *A. hydrophila* SSU infection. To study enolase’s role in the pathogenesis of *A. hydrophila* infections, we immunized mice with the purified recombinant enolase and subsequently challenged them with a lethal dose (5 × 10^7 to 1 × 10^8 CFU) of WT *A. hydrophila*. The deaths were recorded, and mice were observed for 3 weeks after challenge. The mortality rates from both the groups (immunized and nonimmunized) are shown in panel A while the bacterial loads in the livers and spleens of both the groups are shown in panel B. The asterisk denotes statistically significant differences between immunized and nonimmunized groups by a Fisher’s exact test (A) or a Student’s t test (B).

**FIG. 8.** Role of enolase in a mouse model of *A. hydrophila* SSU infection. The recombinant enolase-immunized Swiss Webster mice as well as the nonimmunized mice were intraperitoneally challenged with a lethal dose (2 to 3 LD₅₀) of WT *A. hydrophila*. The deaths were recorded, and mice were observed for 3 weeks after challenge. The mortality rates from both the groups (immunized and nonimmunized) are shown in panel A while the bacterial loads in the livers and spleens of both the groups are shown in panel B. The asterisk denotes statistically significant differences between immunized and nonimmunized groups by a Fisher’s exact test (A) or a Student’s t test (B).

**FIG. 7.** Construction of the chromosomal enolase gene deletion mutant of *A. hydrophila* SSU. (A) The flow diagram showing construction of the mutant. The primer pairs enou5/enou3 and enod5/enod3 (Table 2) were used to PCR amplify the flanking DNA fragments (open boxes) to the enolase gene (dotted box). The Sm/Sp gene cassette was removed from the plasmid pH450L. The suicide vector pDMS197 was used for delivering the construct into WT *A. hydrophila* that contained an additional copy of the enolase gene on the plasmid pBReno. By homologous recombination, the enolase gene on the chromosome of *A. hydrophila* was replaced with the Sm/Sp cassette. The arrows represent the direction and position of different primers. (The figure is not drawn to scale). (B) PCR identification of the potential enolase gene deletion mutants of *A. hydrophila*. In the experiment shown in panel I, the primer set ENT5/Sm3 was used while primer set ENT3/Sm5 was employed for the experiment shown in panel II. Lanes 2 to 5, potential enolase mutant colonies. Other lanes are as indicated.
In the spleen section of nonimmunized mice (panel f), the splenic follicle exhibited necrosis and apoptotic cells in the red pulp in proximity to the lymphoid follicle.

In the immunized group (Fig. 9g, h, and i), the lung section had focal thickening of alveolar septa with lymphohistiocytic infiltrates and neutrophils, but there was no evidence of alveolar hemorrhage or vascular congestion. In the liver section, occasional lobular and perivascular lymphohistiocytic infiltrates with focal areas of necrosis were observed. The increased macrophages in the red pulp and marked lymphoid activation in the splenic follicles, with germinal center formation, were present in the spleen section (panel i). Overall, architectural analysis revealed to us that mice infected with WT *A. hydrophila* without immunization with the recombinant enolase exhibited more severe pathologies. These in vivo data pointed to a disseminative role of the *A. hydrophila* SSU enolase in the infected animals. We also explored whether enolase-specific antibodies altered the phagocytic ability of *A. hydrophila* SSU. For those studies, we precoated bacterial cells with either enolase-specific IgGs or IgGs from preimmune mouse serum. These bacterial cells were then used to infect murine RAW 264.7 macrophages. Our data indicated that macro-

FIG. 9. The histopathological analysis of mouse tissues. Swiss Webster mice immunized with or without the purified recombinant enolase of *A. hydrophila* SSU were challenged i.p. with a lethal dose (2 to 3 LD₅₀) of WT *A. hydrophila*. Mouse organs (liver, lung, and spleen) were removed on day 3 postchallenge and stained with hematoxylin and eosin; the noninfected mice were used as controls. Tissues are as indicated on the figure. Magnifications, ×100 (a, b, c, d, h, and i) and ×200 (e, f, and g).
phages engulfed similar numbers of bacteria precoated with either the purified IgGs from enolase-immunized or preimmune mouse serum (data not shown).

**DISCUSSION**

Enolase’s pathogenic role has been linked to its surface expression and its ability to bind plasminogen in several pathogenic bacteria (1, 3, 11, 20, 26–28, 32). The subsequent activation of the fibrinolytic system promotes bacterial penetration of the barriers of the infected host (2, 3, 11, 20). Several bacterial molecules, such as enolase, the glyceraldehyde-3-phosphate dehydrogenase, and certain fimbrial and flagellar antigens, have been reported to serve as plasminogen receptors (20). The existence of surface plasminogen receptor(s) on *A. hydrophila* SSU cells was evidenced by the binding of plasminogen to the intact bacterial cells and by the ability of bacteria to aid in tPA-mediated plasminogen activation. Importantly, this binding and activation could be partially inhibited by enolase-specific antibodies, which indicated to us that enolase is one of the surface plasminogen receptors and correlated with our previous findings (32).

We also observed that a lysine analog, EACA, inhibited plasminogen binding and activation, which suggested to us that immobilization of plasminogen on the surface of *A. hydrophila* SSU might involve lysine residues of its receptors (e.g., enolase) in binding to the kringle domains of plasminogen (20). As α₂-AP is the primary circulating inhibitor of plasmin, it binds to the kringle domains and effectively inactivates soluble plasmin (17). Consequently, the protection provided by *A. hydrophila* cells to plasmin from the effect of α₂-AP was evidence that the converted plasmin was still in a bound form, and this protection further implicated the involvement of surface-expressed enolase in the pathogenesis of *A. hydrophila* SSU infections.

In addition to using eukaryotic plasminogen activators, such as tPA and urokinase, several pathogenic bacteria also produce their own activators. These may be either surface-bound proteolytic activators, such as the plasminogen activator (Pla) in *Yersinia pestis* and PrtA in *Salmonella enterica*, or nonproteolytic activators, such as staphylokinase and streptokinase, which are secreted by staphylococci and streptococci, respectively (9, 17–20). As we did not detect any significant conversion or activation of plasminogen without tPA in the assays we used, these data provided evidence that *A. hydrophila* SSU lacked a functional plasminogen activator of its own.

We further confirmed plasminogen binding with enolase of *A. hydrophila* SSU by using purified recombinant protein and observed a similar inhibitory role of the lysine analog EACA in the binding. These data strongly suggested involvement of lysine residues in *Aeromonas* enolase-plasminogen binding. It has been shown that the two carboxyl-terminal lysine residues located immediately before the termination codon play a role in enolase-plasminogen binding in both eukaryotic and prokaryotic enolase (1, 23, 27). Interestingly, the *A. hydrophila* SSU enolase did not possess such C-terminal lysine residues (11, 32). However, when the lysine residues of *Aeromonas* enolase (positions 420 and 427) were mutated, we observed decreased plasminogen-binding activities with the mutated forms, which suggested to us that the lysine residues near the C-terminal end of enolase played a role in plasminogen binding. Interestingly, when the lysine residue at position 430 (the closest lysine residue to the C-terminal end of enolase) was replaced with arginine, plasminogen-binding activity was not significantly altered. This could possibly be due to the similarity of arginine to a lysine residue as both are positively charged amino acid residues.

Recently, an internal stretch (amino acid residues 248 to 256) of pneumococcal enolase was identified as the plasminogen-binding motif (3, 11). In this study, we have shown that synthetic peptides corresponding to this internal stretch of *S. pneumoniae* and *A. hydrophila* competitively inhibited plasminogen binding to *A. hydrophila* SSU enolase, and we believe that these peptides represent a binding domain for plasminogen in both *S. pneumoniae* and *A. hydrophila*. A similar binding motif has been reported for the enolase of *L. mexicana* (40).

Ehinger et al. reported that the internal stretch of *S. pneumoniae* was located on the surface of the octameric pneumococcal enolase, whereas the C-terminal lysines were located in the interdimer groove and apparently not accessible to plasminogen binding (11). We observed some additive blocking effects by combining mutated forms of enolase (lysine residues at position 420 or 427) with the synthetic peptide Aeno in a sandwich ELISA (Fig. 6B). However, we need to determine the exact role of these lysine residues and the internal stretch in plasminogen binding in context of the oligomeric status of enolase on the surface of *A. hydrophila* SSU.

It has been reported that the amino acid residues Glu168, Glu211, Lys345, and Lys396 are important for the enzymatic activity of enolase in *Saccharomyces cerevisiae* (26). As expected, when we mutated the corresponding lysine residues of *A. hydrophila* SSU enolase at positions 343 and 394, the enzymatic activities were severely affected. A similar decrease in enzymatic activity was observed when we altered lysine residues at positions 420, 427, and 430 of *Aeromonas* enolase. The enzymatic activity of enolase is associated with its dimeric form (26, 42), and mutations of lysine residues toward the C-terminal end of *Aeromonas* enolase possibly affected its oligomeric form, thereby decreasing enzymatic activity. A recent report noted that replacement of the native enolase gene with the mutated enolase gene (in which both of the C-terminal lysine residues were either replaced or deleted) in the genome of *S. pneumoniae* did not affect the overall enzymatic activity on the surface of these mutated *S. pneumoniae* cells compared to the activity of the native enolase on the surface (3). However, the positions of mutated lysine residues were different in *A. hydrophila* SSU from their positions in *S. pneumoniae*. Further, we used purified recombinant, mutated enolase instead of the surface-expressed mutated enolase to measure the enzymatic activities.

To further study the role of enolase, we started by generating an enolase-negative isogenic mutant of *A. hydrophila* SSU. However, we found that enolase might be essential for the viability of *A. hydrophila*, which was not surprising, as enolase is one of the key enzymes acting as a 2-phospho-d-glycerate hydrolase in the glycolytic cycle located in the cytoplasm of prokaryotes and eukaryotes (1). Further, there was only one copy of the enolase gene in the *A. hydrophila* genome (30, 32). Similar results were reported for *S. pyogenes* and *S. pneumoniae*, in which the enolase gene was indispensable (1, 28). Based on the DNA sequence (gene accession number
knocked out the enolase gene from the chromosome of A. hydrophila SSU with anti-enolase-specific antibodies, genetically proved the role of enolase in the viability of Aeromonas species in general. However, further studies are needed to conclusively prove the role of enolase in the viability of Aeromonas species in general.

In this study, we showed that blocking the surface enolase of A. hydrophila SSU with anti-enolase-specific antibodies, generated by immunizing the mice with purified recombinant enolase, protected animals from subsequent Aeromonas infection. The immunized animals had minimal histopathological changes and lower bacterial loads in the organs examined. This correlated well with the plasminogen-binding ability of Aeromonas enolase and its surface display, which are linked to mediation of infection in the host. We noted that bacteria coated with antibodies to enolase were phagocytosed by macrophages to the same extent as were A. hydrophila SSU cells coated with purified IgGs from the preimmune serum at the same protein concentration. These data ruled out the possibility that enolase antibody-coated bacteria were rapidly engulfed by macrophages and killed, resulting in minimal mouse mortality and histopathology. From our data, it appeared that the surface-displayed enolase had a direct role in disseminating the bacteria to different organs.

Importantly, enolase is a multifunctional protein (26), and it may affect bacterial virulence through different mechanisms. Enolase, especially, has been reported to have the ability to bind cytoskeletal and chromatin structures and is a component of the RNA degradosome in E. coli involved in the degradation of mRNA (7, 26). Thus, enolase might play a role in regulating the expression of a variety of genes, including those coding for identified and unidentified virulence factors of A. hydrophila.

In addition to interaction with the mammalian proteolytic plasminogen-plasmin system, enolase from Streptococcus sobrinus has been reported to suppress the immune system in mice (41). Therefore, further studies that focus on these possibilities will certainly help us to delineate the pathogenic mechanism(s) of A. hydrophila infections that are linked to enolase and will be included in our future research. Although our current study is focused mainly on A. hydrophila SSU, considering the ubiquitous and conservative properties of enolase, its interaction on the cell surface with the mammalian proteolytic plasminogen-plasmin system may represent a universal pathogenic mechanism in Aeromonas infections in general and needs to be further explored.

ACKNOWLEDGMENTS

This research was supported by grants to A.K.C. from the NH/NIH (AI041611) and the Environmental Protection Agency. We thank Mandelle Susman for her carefully editing of the manuscript.

REFERENCES


27. Pancholi, V., and V. A. Fischetti. 1998. α-Enolase, a novel strong plasmin-


